Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan

BioMarin Pharmaceutical Inc. announced today that the United States Patent Office has issued patents covering stable tablet formulation and the approved once daily dosing regimen for Kuvan(R) (sapropterin dihydrochloride) for the treatment of phenylketonuria (PKU).

The details can be read here.

Wockhardt net loss at Rs 190 cr in Q2

Wockhardt, the sixth largest Indian pharmaceutical major, has suffered another setback during the second quarter ended June 2009 and its net loss reached at Rs 189.87 crore as against a net profit of Rs 105.87 crore in the corresponding period of last year.

the details can be read here.

Dr Reddy's launches halometasone cream in India

Dr Reddy's Laboratories Ltd has launched Execare (halometasone cream 0.05 per cent) in India for the treatment of acute/chronic steroid responsive dermatoses and vitiligo.


The details can be read here.

AstraZeneca Submits New Drug Applications for Zactima in Second-Line Advanced Non-Small Cell Lung Cancer

AstraZeneca today announced the company has submitted a New Drug Application to the U.S. FDA and a Marketing Authorisation Application to the European Medicines Agency (EMEA) for an investigational drug,vandetanib 100 mg for use in combination with chemotherapy for the treatment of advanced non-small cell lung cancer in patients previously treated with one prior anti-cancer therapy.

The details can be read here.

FDA Approves Tyvaso (Treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension

United Therapeutics Corporation announced today that the United States Food and Drug Administration (FDA) has approved TYVASO (treprostinil) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH) using the TYVASO Inhalation System (which includes the Optineb-ir device and accessories). TYVASO is indicated to increase walk distance in patients with NYHA Class III symptoms associated with WHO Group I PAH, which includes multiple etiologies such as idiopathic and familial PAH as well as PAH associated with scleroderma and congenital heart disease.


the details can be read here.

Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets

Lotus Pharmaceuticals, Inc. a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic of China, today reported it received notice of patent pending from the State Intellectual Property Office of the People's Republic of China for its innovative patent application of Gliclazide-Controlled Release Tablets submitted in 2008.

the details can be read here.

Wockhardt divests nutrition businesses to Abbott for Rs 630 cr

Wockhardt, a Rs 3,500 crore Mumbai based debt ridden pharma major, has divested its Nutritional businesses to Abbott, the global health care company, for a total consideration of Rs 630 crore (US$130 million) in cash.

The details can be read here.

Cipla net surges by 73% to Rs 242 cr in Q1

Cipla Ltd has achieved impressive growth in bottom line during the first quarter ended June 2009. The net profit went up by 72.6 per cent to Rs 241.71 crore from Rs 140.04 crore in the corresponding period of last year.

The details can be read here.

FDA Issues Complete Response Letter for Intuniv (guanfacine) Extended Release

Shire plc, the global specialty biopharmaceutical company, announces that it has received a Complete Response letter today for INTUNIV(TM) (guanfacine) Extended Release from the FDA.

The details can be read here.

GlaxoSmithKline Withdraws Its Marketing Authorisation Application For Bosatria (Mepolizumab)

July 29, 2009--The European Medicines Agency has been formally notified by GlaxoSmithKline Research & Development Limited of its decision to withdraw the application for a centralised marketing authorisation for Bosatria (mepolizumab), powder for solution for infusion, 250 mg/vial.

the details can be read here.

FDA Approves SculptraAesthetic, a Facial Injectable for Correction of Nasolabial Folds and Other Facial Wrinkles

Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) approved Sculptra Aesthetic (injectable poly-L-lactic acid) for the correction of shallow to deep nasolabial fold (smile lines) contour deficiencies and other facial wrinkles which are treated with the appropriate injection technique in healthy patients.

The details can be read here.

Soliris (Eculizumab), The First and Only Therapy For The Treatment of Patients with PNH, Is Now Available in Canada

Alexion Pharma Canada, a newly incorporated division of Alexion Pharmaceuticals, Inc., today announced the availability in Canada of Soliris(TM) (eculizumab) for the treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH), an ultra-rare, progressive and life-threatening blood disease characterized by chronic haemolysis, or red blood cell destruction.

The details can be read here.

Ranbaxy Gains Approval To Market Ran-Ropinirole Tablets in Canada

Ranbaxy Pharmaceuticals Canada Inc., announced today that RLL has received approval in Canada to manufacture and market Ran-Ropinirole 0.25 mg, 1.0 mg, 2.0 mg, and 5.0 mg tablets (Ropinirole Hydrochloride) from Health Canada, Therapeutic Products Directorate (TPD).

The details can be read here.

Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit

Watson Pharmaceuticals, Inc., a leader in generic and specialty branded pharmaceuticals, today announced a license agreement with GeneraMedix, Inc., for the exclusive US marketing rights to a generic version of Ferrlecit (sodium ferric gluconate complex in sucrose injection), a drug indicated for the treatment of iron deficiency anemia in hemodialysis patients receiving supplemental epoetin therapy.

The details can be read here.

FDA Finalizes Authorized Generics Reporting Rule; Electronic Submissions Will be Permitted and Eventually Required

On July 28, 2009, FDA will publish a final rule amending the Agency’s regulations requiring that NDA holders submit in annual reports certain information to the Agency concerning authorized generics.

The details can be read here.

Suven presents phase-I clinical data of SUVN-502 for Alzheimer's disease

Suven Life Sciences, a biopharma company focused on discovering, developing and commercializing novel pharmaceutical products, has presented clinical phase-I data for SUVN-502, its 5-HT6 antagonist drug candidate at the 2009 Alzheimer's Association International Conference on Alzheimer's disease in Vienna, Austria.

The details can be read here.

Glenmark net dips by 54% to Rs 53 cr in Q1

Glenmark Pharmaceuticals, a Rs 2000 crore pharma giant from Mumbai, has suffered a heavy setback during the first quarter ended June 2009 on account of hefty interest burden and higher depreciation charges. Its consolidated net profit declined by 53.7 per cent to Rs 53.45 crore from Rs 115.38 crore in the corresponding period of last year.

the details can be read here.

Tranzyme Pharma Receives FDA Fast Track Status for Its Oral GI Prokinetic Drug Candidate TZP-102

Jul 27, 2009 - Tranzyme Pharma today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company's oral gastrointestinal (GI) prokinetic drug candidate TZP-102, for the treatment of gastroparesis in diabetic patients.

The details can be read here.

Takeda Submits a New Drug Application for a Fixed-Dose Combination Tablet of Actos with sulfonylurea in Japan

Takeda Pharmaceutical Company Limited announced today that it filed a NDA to the Ministry of Health, Labour and Welfare for a fixed-dose combination tablet of Actos® (pioglitazone HCI) with sulfonylurea for the treatment of type 2 diabetes.

The details can be read here.

Medtronic and Abbott Laboratories Resolve Global Vascular Patent Disputes

Jul 27, 2009 - Medtronic, Inc. today announced global resolution of all outstanding intellectual property litigation with Abbott Laboratories.

The details can be read here.

Taro Receives FDA Approval for Cetirizine Hydrochloride Tablets (OTC) ANDA

Jul 27, 2009 - Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for cetirizine hydrochloride tablets (OTC), 5 mg and 10 mg.

The details can be read here.

Taro Sues Synerx Pharma, Karalex Pharma and DPT Laboratories for Patent Infringement

Jul 27, 2009 - Taro Pharmaceutical Industries Ltd. said today that it has filed a lawsuit against Synerx Pharma, LLC, DPT Laboratories, Ltd. and Karalex Pharma, LLC in the United States District Court for New Jersey for infringement of its United States Patent No. 7,560,445 covering its Ovide® (malathion) Lotion, 0.5%.

The details can be read here.

Allergy Therapeutics gets EU patent for MPL-based sublingual vaccines

Allergy Therapeutics (AGY), the specialist pharmaceutical company focused on allergy vaccination, announced that the European Patent office has granted a broad technology patent relating to the company's family of MPL-based sublingual allergy vaccines.

the details can be read here.

Alcon enters 5-year pact with AstraZeneca for eye drug development

Alcon has entered into a five-year collaborative research agreement with AstraZeneca for the exclusive ophthalmic discovery and potential development rights to AstraZeneca's compound library.

The details can be read here.

Aurobindo Pharma gets US FDA approval for Zidovudine tabs

Aurobindo Pharma Limited, a Rs 2950 crore plus Hyderabad based pharma major, has received the final approval for Zidovudine tablets 60mg (NDA 22-294) and tentative approval for Lamivudine & Zidovudine 30mg / 60mg (NDA 22-296) from the US Food & Drug Administration (US FDA).


The details can be read here.

CytRx's Tamibarotene Receives Positive Opinion from the Committee for Orphan Medicinal Products in the European Union for Treatment of APL

Jul 24, 2009 - CytRx Corporation, a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that its lead drug candidate tamibarotene has received official notification from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) that a positive opinion was made regarding the application for orphan medicinal product for the treatment of acute promyelocytic leukemia (APL).

The details can be read here.

Nycomed’s Instanyl is first intranasal fentanyl approved in Europe for managing breakthrough pain in cancer

July 24, 2009--Nycomed today announced that the European Commission has granted marketing authorisation for Instanyl®, its first-in-class intranasal fentanyl spray.

The details can be read here.

Teva and Ortho-McNeil-Janssen Settle Ortho Tri-Cyclen Lo Litigation

Jul 24, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has entered into a definitive agreement with Ortho-McNeil-Janssen to settle the patent infringement lawsuit in the U.S. District Court for the District of New Jersey related to Teva's generic version of the oral contraceptive, Ortho Tri-Cyclen® Lo.

The details can be read here.

Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and Actos (pioglitazone HCl)

Takeda Pharmaceutical Company Limited today announced that Takeda has received notification from the U.S. FDA that the FDA extended the review of the New Drug Application for the fixed-dose combination (FDC) of alogliptin and ACTOS (pioglitazone HCl).

The details can be read here.

Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma

Schering-Plough today announced that a New Drug Application (NDA) for a fixed-dose combination of mometasone furoate and formoterol fumarate has been filed in the United States and accepted for review by the U.S. Food and Drug Administration (FDA).

The details can be read here.

FDA Approves Expanded Use of Lilly's Forteo [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis

Eli Lilly and Company announced that the U.S. FDA has approved a new use for its osteoporosis drug FORTEO [teriparatide injection] to treat osteoporosis associated with sustained, systemic glucocorticoid therapy in men and women at high risk of fracture.

The details can be read here.

Allergan Receives FDA Approval for Acuvail Ophthalmic Solution for the Treatment of Pain and Inflammation Following Cataract Surgery

Jul 23, 2009 - Allergan, Inc. today announced that the United States Food and Drug Administration (FDA) has approved ACUVAIL™ (ketorolac tromethamine ophthalmic solution) 0.45%, an advanced, preservative-free formulation of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain and inflammation following cataract surgery.

The details can be read here.

Sabcomeline patent filing

July 22, 2009--Minster Pharmaceuticals plc, the drug development company specialising in neurological and psychiatric disorders, is pleased to announce that it has just received confirmation that it has successfully filed a divisional application in the USA covering a method of adjunct therapy using sabcomeline to treat a psychotic disorder, more particularly to treat the negative and cognitive symptoms associated with schizophrenia. Based on an opinion obtained from Minster’s US attorney, the Company has confidence that these claims are patentable and should therefore be granted.

the details can be read here.

Synthon announces European approvals for generic Rivastigmine

21 July 2009 -- Synthon is announcing that it has successfully completed multiple decentralized procedures (DCP) for Rivastigmine. Regulatory clearance has been obtained for Synthon's product in nearly all European countries.

The details can be read here.

Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government

Human Genome Sciences, Inc. today announced that the U.S. Government has exercised its option to purchase an additional 45,000 doses of raxibacumab (ABthrax(TM)) for the Strategic National Stockpile, to be delivered over a three-year period, beginning near the end of 2009. HGS expects to receive approximately $151 million from this award as deliveries are completed.

The details can be read here.

NewBridge Pharmaceuticals Announces Licensing of Pylera for Middle East, Africa, Turkey & Caspian Region

NewBridge Pharmaceuticals, a specialty pharmaceutical, biologics, and medical device company serving the Middle East, Africa, Turkey & Caspian regions, today announced that it has entered into an exclusive license and supply agreement with Axcan Pharma for Pylera , an innovative 3-in-1 capsule therapy for the eradication of Helicobacter pylori, a bacterium now recognized as being the main cause of gastric and duodenal ulcers.

The details can be read here.

Depomed Provides License for Patents Covering Metformin Extended Release Technology to Merck & Co., Inc.

Jul 22, 2009 - Depomed, Inc. today announced that it has provided a license to certain patents directed to metformin extended release technology to Merck & Co., Inc. to be used in developing fixed dose combinations of sitagliptin and extended release metformin.

The details can be read here.

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that the Swiss agency for therapeutic products, Swissmedic, has issued a marketing authorisation for Moapar(R) 11.25mg, the first 3-month injectable formulation, prescribed for a reversible reduction of serum testosterone to the level of castration in adult men suffering from sexual deviations.

The details can be read here.

FDA Approves Tekturna HCT as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent

The US FDA has approved Tekturna HCT (aliskiren and hydrochlorothiazide) tablets as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals.

The details can be read here.

Avidas Pharmaceuticals and LaRon Pharma Inc. Announce Co-Promotion Agreement

Avidas Pharmaceuticals and LaRon Pharma Inc. today announced that they have entered into an agreement for LaRon to co-promote Avidas' key prescription-only convenience kits, Avidoxy(TM) DK defence kit and Scalacort(TM) DK defence kit. Under the terms of the agreement, LaRon will provide sales support focused on primary care and internal medicine physicians in the United States, while Avidas will continue its sales force specialty focus in dermatology.

The details can be read here.

Zarzio (filgrastim) now available in the UK for the treatment of neutropenia associated with chemotherapy or HIV infection1

July 21, 2009 – Sandoz launches Zarzio(filgrastim), a recombinant granulocyte colony-stimulating factor (G-CSF) for the treatment of neutropenia (low white blood cell count) associated with chemotherapy treatment or advanced HIV infection and the mobilisation of peripheral blood progenitor cells1.

The details can be read here.

Ranbaxy Receives Final Approval to Manufacture and Market Ran-Simvastatin Tablets in Canada

Ranbaxy Pharmaceuticals Canada Inc., a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval in Canada to manufacture and market Ran-Simvastatin 5 mg, 10 mg, 20 mg, 40 mg and 80 mg tablets (Simvastatin) from Health Canada, Therapeutic Products Directorate (TPD).

The details can be read here.

Pharmalucence, Inc. Announces FDA Approval for its Generic Sestamibi Kit

Jul 20, 2009 - Pharmalucence, Inc., a leading supplier of radiopharmaceutical products, announced today that it received approval from the U. S. FDA Office of Generic Drugs for its ANDA to manufacture and market its Kit for the Preparation of Technetium Tc-99m Sestamibi Injection.

The details can be read here.

A.P. Pharma Announces FDA Acceptance of APF530 New Drug Application for Chemotherapy-Induced Nausea and Vomiting

Jul 20, 2009 - A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that the U.S. FDA has accepted for review the New Drug Application (NDA) for APF530 for the potential treatment of chemotherapy-induced nausea and vomiting (CINV). APF530 is a long-acting formulation of granisetron that utilizes the Company's proprietary Biochronomer™ drug delivery system.

The details can be read here.

ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer

Jul 20, 2009 - ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY), and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. FDA has approved revisions to the U.S. prescribing information for ERBITUX® (cetuximab) concerning the treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC).

The details can be read here.

Shire gets fast track status for velaglucerase alfa to treat Gaucher disease

Shire plc, the global specialty biopharmaceutical company, has received Fast Track designation from the US FDA for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of type-I Gaucher disease.

The details can be read here.

Tibotec Pharma, Gilead Sciences ink pact for fixed-dose antiretroviral product to treat HIV-1 adult patients

Tibotec Pharmaceuticals has entered into a license and collaboration agreement with Gilead Sciences, Inc for the development and commercialization of a new once-daily fixed-dose antiretroviral product containing Tibotec's investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride 25 mg) and Gilead's Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) for treatment-naïve adult patients with HIV-1.

the details can be read here.

Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix (Panitumumab)

Amgen Inc. today announced the U.S. Food and Drug Administration (FDA) has approved revisions to the U.S. prescribing information for the epidermal growth factor receptor (EGFr) class of antibodies, including Vectibix (panitumumab).

The details can be read here.

Teva Provides Update on Generic Ortho Tri-Cyclen Lo

Jul 17, 2009 - Teva Pharmaceutical Industries Ltd. announced today that further to its press release dated July 7, 2009, the Company and Ortho McNeil Janssen have extended their agreement to cease shipments of generic versions of Ortho Tri-Cyclen® Lo, until the earlier of (a) the Court's ruling on the motion for preliminary injunction or (b) July 29.

The details can be read here.

Gonal-f Approved in Japan for Ovulation Induction in Infertile Women

July 16, 2009 – Merck KGaA announced today that the Japanese Ministry of Health, Labor and Welfare has granted approval to extend the indication of Gonal-f® (follitropin alfa for injection) to infertile women suffering from irregular or no ovulation (oligoovulation or anovulation) due to a dysfunction in the hypothalamic-pituitary system or polycystic ovarian syndrome. Gonal-f is a recombinant follicle-stimulating hormone currently approved in Japan for the treatment of male infertility.

The details can be read here.

BioDelivery Sciences and Meda Announce FDA Approval of ONSOLIS

BioDelivery Sciences International, Inc. and Meda AB today announced approval from the U.S. FDA to market ONSOLIS™ (fentanyl buccal soluble film), formerly referred to as BEMA™ Fentanyl, for the management of breakthrough pain (BTP) in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

The details can be read here.

Taro Receives Patent for Ovide

Taro Pharmaceutical Industries Ltd. announced that the U.S. Patent and Trademark Office has issued a patent covering its Ovide(r) (malathion) lotion, 0.5% (patent no. US 7,560,445).

The details can be read here.

Bedford Laboratories to Begin Shipping Ceftriaxone for Injection USP

Bedford Laboratories(TM), a division of Ben Venue Laboratories, Inc., announced FDA approval to begin shipping Ceftriaxone for Injection USP. This product is AP rated and is equivalent to Rocephin by Roche.

the details can be read here.

Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. FDA for its Abbreviated New Drug Application for Liothyronine Sodium Tablets USP, 5 mcg (base), 25 mcg (base) and 50 mcg (base).

The details can be read here.

Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR

Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, has filed an ANDA with the U.S. FDA seeking approval to market its trospium chloride extended-release 60 mg capsules prior to the expiration of a patent owned by Supernus Pharmaceuticals, Inc. Watson's trospium chloride extended-release capsules are the generic version of Allergan Inc.'s Sanctura XR product, which is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.

The details can be read here.

Plan B One-Step—New FDA-Approved One-Pill Emergency Contraceptive

Teva Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for Plan B® One-Step emergency contraception (levonorgestrel tablet, 1.5 mg).

The details can be read here.

Wyeth's Prevenar 13* Receives First Approval

Wyeth Pharmaceuticals, a division of Wyeth, announced today that the Chilean Ministry of Health, MINSAL (Ministerio de Salud), has become the first government agency to approve Prevenar 13* Valent, (Pneumococcal Conjugate Vaccine 13 Valent (Diphtheria CRM(197) Protein)) for infants and young children.

The details can be read here.

Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient

Daiichi Sankyo, Inc. and Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) approved Effient(TM) (prasugrel) tablets for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI).

The details can be read here.

Alimta (pemetrexed for injection) First Agent Approved in Europe as Maintenance Therapy for Advanced, Nonsquamous Non-Small Cell Lung Cancer

Eli Lilly and Company announced today that the European Commission has granted approval for the use of ALIMTA(R) (pemetrexed for injection) as monotherapy for maintenance treatment of patients with other than predominantly squamous cell histology in locally-advanced or metastatic non-small cell lung cancer (NSCLC), whose disease has not progressed immediately following platinum-based chemotherapy.

The details can be read here.

Asmanex (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients

Schering-Plough Corporation today announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for ASMANEX TWISTHALER (mometasone furoate dry powder inhaler) for the treatment of bronchial asthma in adults.

The details can be read here.

MannKind Announces Positive New Market Survey Information Regarding AFRESA®

MannKind Corporation today released new information related to the market potential for AFRESA, MannKind's ultra rapid-acting insulin.

The details can be read here.

ratiopharm Canada wins important patent legal battle with Pfizer

ratiopharm Canada is pleased to announce that it has won a five-year legal battle against Pfizer to allow the marketing of Amlodipine Besylate (Norvasc(R)) by Canadian generic manufacturers. ratiopharm was the first company to challenge the Amlodipine Besylate patent in 2004 and the only company to successfully see the case through to the Federal Court decision announced on July 8, 2009.

The details can be read here.

Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to Lexapro Patent Litigation

Forest Laboratories, Inc. and its wholly-owned subsidiary, Forest Laboratories Holdings, Ltd., and H. Lundbeck A/S announced today that they have entered into a settlement agreement with Sun Pharmaceutical Industries Ltd. and Caraco Pharmaceutical Laboratories, Ltd., regarding pending patent infringement disputes regarding U.S. Patent Re. No. 34,712, U.S. Patent No. 6,916,941, and U.S. Patent No. 7,420,069, which were licensed to Forest by H. Lundbeck A/S on an exclusive basis in the United States.

The details can be read here.

Sun Pharma to License Key Escitalopram Patent Applications to Lundbeck

Sun Pharmaceutical Industries Ltd. announced that along with Caraco Pharmaceutical Laboratories, Ltd, it had entered into agreements with Forest Laboratories, Inc., Forest Laboratories Holdings, Ltd., and H. Lundbeck A/S to settle the legal proceedings related to Lexapro® (escitalopram oxalate) tablets.

The details can be read here.